Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SINK: Scheduled Intranasal Ketamine for Traumatic Pain
NCT05671913Phase 1Withdrawn
- Sponsor
- Sanford Health
- Start
- Jan 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
01
Overview
Phase 1, randomised trial in acute pain comparing Intranasal Ketamine with Placebo (2 arms). Primary endpoint: Total Morphine Equivalents at 72 hours. Planned start Jan 2023; status: withdrawn.
02
Drugs
ketamine
03
Conditions
acute pain
Beyond the preview
Go deeper on NCT05671913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05671913.